136 related articles for article (PubMed ID: 36097900)
1. [Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast].
Gao BB; Zheng Q; Yu L; Luo DJ; Nie X; Xu X
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):843-849. PubMed ID: 36097900
[No Abstract] [Full Text] [Related]
2. Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast.
Lei T; Pu T; Wei B; Fan Y; Yang L; Shen M; Chen M; Yang J; Zhang Y; Zhang Z; Bu H
J Clin Pathol; 2022 Jan; 75(1):18-23. PubMed ID: 33214199
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast.
Honda M; Saji S; Horiguchi S; Suzuki E; Aruga T; Horiguchi K; Kitagawa D; Sekine S; Funata N; Toi M; Kuroi K
Surg Today; 2011 Mar; 41(3):328-32. PubMed ID: 21365411
[TBL] [Abstract][Full Text] [Related]
4. Preoperative MRI of breast squamous cell carcinoma: diagnostic value of distinguishing between two subtypes.
Chen S; Du Y; Hu Y; Ling R; Huang D; Xiang J; Liang Y; Wei X; Tang W; Guo Y
Clin Radiol; 2022 Apr; 77(4):e321-e328. PubMed ID: 35093233
[TBL] [Abstract][Full Text] [Related]
5. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
7. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
9. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
11. Metaplastic Carcinoma of the Breast: Analysis of 38 Cases from a Single Institute.
Hasbay B; Bolat FA; Aytaç HÖ; Aslan H; Purbager A
Turk Patoloji Derg; 2020; 36(1):23-30. PubMed ID: 31769499
[TBL] [Abstract][Full Text] [Related]
12. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
Chartier S; Brochard C; Martinat C; Coussy F; Feron JG; Kirova Y; Cottu P; Marchiò C; Vincent-Salomon A
Histopathology; 2023 Apr; 82(5):664-671. PubMed ID: 36527253
[TBL] [Abstract][Full Text] [Related]
13. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
14. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
15. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
[TBL] [Abstract][Full Text] [Related]
16. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients.
Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Kim S; Choe JH; Lee JE; Kim JH; Kim JS; Nam SJ; Yang JH
Breast Cancer Res Treat; 2011 Apr; 126(2):471-8. PubMed ID: 21287362
[TBL] [Abstract][Full Text] [Related]
17. Spindle cell metaplastic carcinoma of breast: A clinicopathological and immunohistochemical analysis.
Zhu H; Li K; Dong DD; Fu J; Liu DD; Wang L; Xu G; Song LH
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e72-e78. PubMed ID: 25483573
[TBL] [Abstract][Full Text] [Related]
18. Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma.
Zhao D; Fu X; Rohr J; Wang Y; Li M; Zhang X; Qin J; Xu M; Li C; Sun G; Wang Z; Guo S
Pathol Res Pract; 2021 Dec; 228():153677. PubMed ID: 34775151
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]